TECFIDERA

Type: Keyphrase
Name: TECFIDERA
First reported 6 hours ago - Updated 6 hours ago - 1 reports

Multiple sclerosis treatment landscape has undergone dramatic changes during 2013

(live-PR.com) - The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen´s Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market share from older therapies. However, ... [Published Live-PR.com - 6 hours ago]
First reported Jul 29 2014 - Updated Jul 29 2014 - 2 reports

Can Biogen Idec Take Wing With Tecfidera?

By William Meyers :Biogen Idec (NASDAQ: BIIB ) generates most of its revenue from drugs for MS ( multiple sclerosis ), but also receives substantial sums from other disease indications. It recently has gained approval for its hemophilia therapies. Biogen ... [Published BioPortfolio - Jul 29 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Results of pending MS trial may show whether Biogen has another blockbuster

With the success of its blockbuster multiple sclerosis drug Tecfidera, Biogen Idec has already made its name as the most recognized world leaders in drugs for that disease. But the results of a mid-stage trial expected in coming months could indicate ... [Published Boston Business Journal - Jul 29 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Plegridy approval underlines Biogen Idec's dominance in MS

Biogen Idec added a fifth product to its multiple sclerosis (MS) franchise last week after the European Commission approved long-acting interferon Plegridy.Plegridy (peginterferon beta-1a) is a long-acting version of Biogen Idec's big-selling Avonex (interferon ... [Published PMLive - Jul 28 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

3 Reasons Why Biogen Stock Is Still a Buy (BIIB)

Popular Posts: Recent Posts: Growth-oriented investors looking for exposure to the burgeoning biotech sector could find a gem that’s already exploding in Biogen Idec ( BIIB ).Although BIIB stock has gained more than 20% year to date, this week’s blockbuster ... [Published InvestorPlace.com - Jul 25 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 2 reports

Tecfidera not working p!!!

Hi all I'm back again my yearly or so problem check in :/ maybe you might recall me I started tecfidera in Sept, repeat MRI 7 months later showed multiple new and enhancing lesions obviously this drug is not for me eitherNot surprised this is my 4th ... [Published HealthBoards - Jul 25 2014]
Entities: TECFIDERA, Rebif, Gilenya
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Gilead, Merck HCV marketing battle may be on horizon

Share this article: The biggest story of Gilead's second quarter was supposed to be Sovaldi's astronomical sales figures, but its progress on protease inhibitor GS-9857—which could serve as stiff competition for the asset Merck acquired in its recent ... [Published Medical Marketing And Media - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

What Makes Biogen Idec a Biotech Standout?

Source: ThinkstockIn biotechnology there is a new class of high-flying, multibillion dollar companies like Biogen Idec Inc ( NASDAQ:BIIB ), Regeneron Pharmaceuticals ( NASDAQ:REGN ), and Alexion Pharmaceuticals ( NASDAQ:ALXN ). With exceptional growth, ... [Published Wall St. Cheat Sheet - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

What Makes Biogen Idec a Biotech Standout?

Source: Thinkstock In biotechnology there is a new class of high-flying, multibillion dollar companies like Biogen Idec Inc ( NASDAQ:BIIB ), Regeneron Pharmaceuticals ( NASDAQ:REGN ), and Alexion Pharmaceuticals ( NASDAQ:ALXN ). With exceptional ... [Published Wall St. Cheat Sheet - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 16 reports

Biogen, Gilead Earnings Crush Q2 Estimates

Big-cap biotech leaders Biogen Idec (BIIB) and Gilead Sciences (GILD) easily beat second-quarter earnings estimates and received product approvals Wednesday, but their stocks reacted very differently.Biogenearnings rose 52% vs. a year earlier to $3.49 ... [Published Yahoo! Finance - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 5 reports

-Biogen revenue trounces forecast as MS drug sales surge

(Corrects paragraph 7 to identify Chris Raymond as an analyst at Robert Baird and Co, not Raymond James) By Ransdell Pierson July 23 (Reuters) - Biogen Idec Inc reported blowout quarterly results and raised its full-year forecast on Wednesday on surging ... [Published Sharenet - Jul 23 2014]
First reported Jul 11 2014 - Updated Jul 11 2014 - 4 reports

NICE issues positive draft FAD guidance on Tecfidera

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has issued the Final Appraisal Determination (FAD) today for US biotech firm Biogen Idec’s (Nasdaq: BIIB) new oral multiple sclerosis (MS) drug Tecfidera (dimethyl ... [Published Pharma Letter - Jul 11 2014]

Quotes

"This past quarter highlighted significant accomplishments across our business, from the approval of ELOCTATE for hemophilia A, to the continued patient uptake of TECFIDERA in the U S and new markets worldwide, to strong clinical results for important emerging MS treatments" said CEO George A Scangos, Ph D
If all goes according to plan Biogen Idec will eventually have "six important medicines to offer MS patients with different needs" said chief executive George Scangos last week, who said that - despite the availability of oral therapies for MS - interferons will continue to play...
...and determine the therapeutic utility and differentiating features of ALKS 8700," said Dr Elliot Ehrich, Chief Medical Officer of Alkermes. "ALKS 8700 leverages Alkermes' expertise in prodrug chemistry and oral controlled-release formulations to offer potential differentiated tolerability and dosing for patients with MS."
...guidance but only met consensus (expectation), which was already above management's projections," said RBC Capital Markets analyst Michael Yee. "So lots of biotech investors are continuing to flock to Gilead and Biogen, which have more near-term earnings upside and catalysts coming."

More Content

All (172) | News (102) | Reports (1) | Blogs (66) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Dealing with MS fatigue – what works? [Published MSology - 2 hours ago]
Multiple sclerosis treatment landscape has unde... [Published Live-PR.com - 6 hours ago]
Copaxone and Avonex generated global sales of U... [Published Live-PR.com - 7 hours ago]
Can Biogen Idec Take Wing With Tecfidera? [Published BioPortfolio - Jul 29 2014]
Can Biogen Idec Take Wing With Tecfidera? [Published Seeking Alpha - Jul 29 2014]
Results of pending MS trial may show whether Bi... [Published Boston Business Journal - Jul 29 2014]
Biogen Idec Q2 profit jumps, beats estimate [Published MyIris - Jul 29 2014]
Jim Cramer Talks Dollar Tree (DLTR), Apple (AAP... [Published TheStreet.com - Jul 28 2014]
Jim Cramer Talks Dollar Tree (DLTR), Apple (AAP... [Published The Street Latest - Jul 28 2014]
Plegridy approval underlines Biogen Idec's domi... [Published PMLive - Jul 28 2014]
3 Reasons Why Biogen Stock Is Still a Buy (BIIB) [Published InvestorPlace.com - Jul 25 2014]
Tecfidera not working p!!! [Published HealthBoards - Jul 25 2014]
Alkermes initiates Phase I multiple sclerosis s... [Published Individual.com - Jul 25 2014]
Tecfidera not working !!!! [Published HealthBoards - Jul 25 2014]
Gilead, Merck HCV marketing battle may be on ho... [Published Medical Marketing And Media - Jul 24 2014]
What Makes Biogen Idec a Biotech Standout? [Published Wall St. Cheat Sheet - Jul 24 2014]
What Makes Biogen Idec a Biotech Standout? [Published Wall St. Cheat Sheet - Jul 24 2014]
UPDATE 2-Celgene profit rises but revised outlo... [Published Reuters - Jul 24 2014]
Transcript: Wednesday, July 23, 2014 [Published NBR.com - Jul 24 2014]
The Zacks Analyst Blog Highlights: AbbVie, Shir... [Published Yahoo! Finance - Jul 24 2014]
Biogen, Gilead Earnings Crush Q2 Estimates [Published Yahoo! Finance - Jul 23 2014]
Sales of Biogen MS pill pick up overseas [Published Medical Marketing And Media - Jul 23 2014]
Markets Mostly Higher As Earnings Season Contin... [Published Benzinga.com - Jul 23 2014]
Biogen Stock's Tecfidera Embarrasses Wall Street [Published Motley Fool Discussion Boards - Jul 23 2014]
Biogen Idec's (BIIB) CEO George Scangos on Q2 2... [Published Seeking Alpha - Jul 23 2014]
Biogen Idec Beats And Raises: Reassessing Its P... [Published Seeking Alpha - Jul 23 2014]
Alkermes Announces Initiation of Phase 1 Clinic... [Published 4 Traders - Jul 23 2014]
-Biogen revenue trounces forecast as MS drug sa... [Published Sharenet - Jul 23 2014]
Biotech Stock Roundup: AbbVie's Tax Inversion, ... [Published Nasdaq - Jul 23 2014]
Report: Over Half of MS Patients Treated With T... [Published PT Community - Jul 23 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Dealing with MS fatigue – what works? [Published MSology - 2 hours ago]
Most people with multiple sclerosis experience fatigue. It’s not the normal feeling of being tired, but more of a sick weariness that sucks the energy out of mind and body. It’s hard to explain to a boss, a spouse or the kids. Also inexplicable is the ...
Tecfidera not working p!!! [Published HealthBoards - Jul 25 2014]
Hi all I'm back again my yearly or so problem check in :/ maybe you might recall me I started tecfidera in Sept, repeat MRI 7 months later showed multiple new and enhancing lesions obviously this drug is not for me eitherNot surprised this is my 4th ...
Tecfidera not working !!!! [Published HealthBoards - Jul 25 2014]
Hi all I'm back again my yearly or so problem check in :/ maybe you might recall me :)I started tecfidera in Sept, repeat MRI 7 months later showed multiple new and enhancing lesions obviously this drug is not for me either :(Not surprised this is my ...
What Makes Biogen Idec a Biotech Standout? [Published Wall St. Cheat Sheet - Jul 24 2014]
Source: Thinkstock In biotechnology there is a new class of high-flying, multibillion dollar companies like Biogen Idec Inc ( NASDAQ:BIIB ), Regeneron Pharmaceuticals ( NASDAQ:REGN ), and Alexion Pharmaceuticals ( NASDAQ:ALXN ). With exceptional ...
Over Half of Audited Multiple Sclerosis Patient... [Published PR Newswire: Entertainment & Media - Jul 22 2014]
BURLINGTON, Mass., July 22, 2014 /PRNewswire/ -- Decision Resources Group finds that over half of audited multiple sclerosis (MS) patients currently treated with Biogen Idec's oral disease-modify therapy (DMT) Tecfidera have ever experienced flushing ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
ShangPharma nomme le dirigeant de l'industrie p... [Published PR Newswire - Oct 25 2013]
ShangPharma ernennt Führungskraft der Pharma-Br... [Published PR Newswire - Oct 25 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.